GlassScriptPhysician profile
Sukhdeep S Padda
NPI 1437143872
$17,096.30
in general payments reported to CMS, 2019-2025
42 companies · $4,296 in 2025
The $4,296 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,269 · 2020: $461 · 2021: $164 · 2022: $1,862 · 2023: $4,013 · 2024: $4,031 · 2025: $4,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,150.86 |
| Education | $188.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,246.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,582.15 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,173.46 | 2019-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $1,012.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $969.94 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $901.53 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $808.46 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $786.51 | 2022-2025 | |
| Pfizer INC. | $623.62 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $552.29 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $498.71 | 2023-2025 | Iqirvo, Bylvay |
| Celgene Corporation | $427.50 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $400.81 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $359.50 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $315.11 | 2019-2024 | Linzess |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $276.68 | 2019-2025 | Ocaliva |
| Alnylam Pharmaceuticals INC. | $246.19 | 2023 | Amvuttra, Givlaari |
| Ardelyx, INC. | $225.68 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $203.56 | 2022-2024 | Dificid |
| Fresenius Kabi USA, LLC | $149.74 | 2023-2024 | Idacio |
| Celltrion USA INC. | $147.69 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Aimmune Therapeutics, INC. | $132.78 | 2024-2025 | Vowst, Zenpep |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
| Tesaro, INC. | $124.99 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $96.80 | 2024 | Fujifilm |
| Nestle Healthcare Nutrition INC. | $72.55 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.69 | 2023-2024 | Cyltezo |
| Olympus America INC. | $66.82 | 2023-2025 | Single Use Repositionable Clip, Endoclot Phs, Visiglide |
| Braintree Laboratories, INC. | $53.32 | 2019 | |
| Lucid Diagnostics INC. | $52.72 | 2024 | |
| Daiichi Sankyo INC. | $50.53 | 2019-2020 | |
| Redhill Biopharma INC. | $49.88 | 2020-2022 | |
| Abbott Laboratories | $48.04 | 2021 | |
| Shionogi INC | $45.76 | 2019 | |
| Ferring Pharmaceuticals INC. | $42.19 | 2023 | Rebyota |
| Allergan, INC. | $28.26 | 2019 | |
| Orphalan INC | $27.33 | 2025 | Cuvrior |
| Capsovision, INC. | $25.34 | 2023 | Capsocam Plus |
| Novo Nordisk INC | $23.54 | 2025 | Wegovy |
| Medtronic, INC. | $18.88 | 2021 | |
| W. L. Gore & Associates, INC. | $18.19 | 2022 | |
| Medtronic USA, INC. | $15.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukhdeep Padda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.